Our data indicate that, due to heterogeneous distribution of the Ki67 antigen, CNB may not adequately represent its true biologic profile and Ki67 should be detected on both CNB and OEB in order to avoid misclassifying tumor subtypes and omission of life-saving systemic therapy, especially on HR+/HER2- tumors. This evidence concerns the gene ERBB2 and neoplasm.